Vergence/accommodative therapy for symptomatic convergence insufficiency in children: Time course of improvements in convergence function.
convergence insufficiency
near-point of convergence
positive fusional vergence
treatment kinetics
vergence/accommodative therapy
Journal
Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)
ISSN: 1475-1313
Titre abrégé: Ophthalmic Physiol Opt
Pays: England
ID NLM: 8208839
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
23
09
2022
received:
14
06
2022
accepted:
23
09
2022
pmc-release:
01
01
2024
pubmed:
23
10
2022
medline:
15
12
2022
entrez:
22
10
2022
Statut:
ppublish
Résumé
To evaluate the time course of improvements in clinical convergence measures for children with symptomatic convergence insufficiency treated with office-based vergence/accommodative therapy. We evaluated convergence measures from 205, 9- to 14-year-old children with symptomatic convergence insufficiency randomised to office-based vergence/accommodative therapy in the Convergence Insufficiency Treatment Trial - Attention and Reading Trial (CITT-ART). Near-point of convergence (NPC) and near-positive fusional vergence (PFV) were measured at baseline and after 4, 8, 12 and 16 weeks of therapy; mean change in NPC and PFV between these time points were compared using repeated measures analysis of variance. Rates of change in NPC and PFV from: (1) baseline to 4 weeks and (2) 4-16 weeks were calculated. For each time point, the proportion of participants to first meet the normal criterion for NPC (<6 cm), PFV blur (break if no blur; >15Δ and >2 times the exodeviation) and convergence composite (NPC and PFV both normal) were calculated. The greatest change in NPC and PFV (7.6 cm and 12.7 Δ) and the fastest rate of improvement in NPC and PFV (1.9 cm/week and 3.2 Δ/week, respectively) were both found during the first 4 weeks of therapy, with both slowing over the subsequent 12 weeks. After 12 weeks of therapy, the NPC, PFV and convergence composite were normal in 93.2%, 91.7% and 87.8% of participants, respectively, and normalised with another 4 weeks of therapy in 4.4%, 2.0% and 4.4% of participants, respectively. Although the greatest improvements in NPC and PFV occurred in the first 4 weeks of therapy, most participants had weekly improvements over the subsequent 12 weeks of treatment. While most children with convergence insufficiency obtained normal convergence following 12 weeks of therapy, an additional 4 weeks of vergence/accommodative therapy may be beneficial for some participants.
Identifiants
pubmed: 36271753
doi: 10.1111/opo.13062
pmc: PMC9798873
mid: NIHMS1841614
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-115Subventions
Organisme : NEI NIH HHS
ID : U10 EY022587
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY022594
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY022592
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY022586
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY022601
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY022599
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY022591
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY022596
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY022595
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY022600
Pays : United States
Investigateurs
Jeffrey Cooper
(J)
Erica Schulman
(E)
Kimberly Hamian
(K)
Danielle Iacono
(D)
Steven Larson
(S)
Valerie Leung
(V)
Sara Meeder
(S)
Elaine Ramos
(E)
Steven Ritter
(S)
Audra Steiner
(A)
Alexandria Stormann
(A)
Marilyn Vricella
(M)
Xiaoying Zhu
(X)
Susanna Tamkins
(S)
Naomi Aguilera
(N)
Elliot Brafman
(E)
Hilda Capo
(H)
Kara Cavuoto
(K)
Isaura Crespo
(I)
Monica Dowling
(M)
Kristie Draskovic
(K)
Miriam Farag
(M)
Vicky Fischer
(V)
Sara Grace
(S)
Ailen Gutierrez
(A)
Carolina Manchola-Orozco
(C)
Maria Martinez
(M)
Craig McKeown
(C)
Carla Osigian
(C)
Tuyet-Suong Pham
(TS)
Leslie Small
(L)
Natalie Townsend
(N)
Michael Gallaway
(M)
Mark Boas
(M)
Christine Calvert
(C)
Tara Franz
(T)
Amanda Gerrouge
(A)
Donna Hayden
(D)
Zachary Margolies
(Z)
Jenny Myung
(J)
Karen Pollack
(K)
Ruth Shoge
(R)
Andrew Tang
(A)
Noah Tannen
(N)
Lynn Trieu
(L)
Luis Trujillo
(L)
Michelle Buckland
(M)
Allison Ellis
(A)
Jennifer Fogt
(J)
Catherine McDaniel
(C)
Taylor McGann
(T)
Ann Morrison
(A)
Shane Mulvihill
(S)
Adam Peiffer
(A)
Maureen Plaumann
(M)
Gil Pierce
(G)
Julie Preston
(J)
Kathleen Reuter
(K)
Nancy Stevens
(N)
Jake Teeny
(J)
Andrew Toole
(A)
Douglas Widmer
(D)
Aaron Zimmerman
(A)
Carmen Barnhardt
(C)
Eric Borsting
(E)
Raymond Chu
(R)
Susan Parker
(S)
Dashaini Retnasothie
(D)
Judith Wu
(J)
Richard Hertle
(R)
Penny Clark
(P)
Kelly Culp
(K)
Kathy Fraley
(K)
Drusilla Grant
(D)
Nancy Hanna
(N)
Stephanie Knox
(S)
William Lawhon
(W)
Lan Li
(L)
Sarah Mitcheff
(S)
Isabel Ricker
(I)
Casandra Solis
(C)
Palak Wall
(P)
Samantha Zaczyk
(S)
Wendy Marsh-Tootle
(W)
Michelle Bowen
(M)
Terri Call
(T)
Kristy Domnanovich
(K)
Marcela Frazier
(M)
Nicole Guyette
(N)
Oakley Hayes
(O)
John Houser
(J)
Sarah Lee
(S)
Jenifer Montejo
(J)
Tamara Oechslin
(T)
Candace Turner
(C)
Katherine Weise
(K)
Rachel Coulter
(R)
Annette Bade
(A)
Surbhi Bansal
(S)
Laura Falco
(L)
Katherine Green
(K)
Gabriela Irizarry
(G)
Jasleen Jhajj
(J)
Nicole Patterson
(N)
Jacqueline Rodena
(J)
Yin Tea
(Y)
Dana Weiss
(D)
Lauren Zakaib
(L)
Ingryd Lorenzana
(I)
Yesena Meza
(Y)
Ryan Mann
(R)
Mariana Quezada
(M)
Scott Rein
(S)
Indre Rudaitis
(I)
Susan Stepleton
(S)
Beata Wajs
(B)
Maryann Redford
(M)
Richard Hertle
(R)
Maryann Redford
(M)
Carolyn Denton
(C)
Eugene Arnold
(E)
Eric Borsting
(E)
Christopher Chase
(C)
Carolyn Denton
(C)
Sharyl Wee
(S)
Katlynn Dahl-Leonard
(K)
Kenneth Powers
(K)
Amber Alaniz
(A)
Marie Diener-West
(M)
William V Good
(WV)
David Grisham
(D)
Christopher J Kratochvil
(CJ)
Dennis Revicki
(D)
Jeanne Wanzek
(J)
Karen Pollack
(K)
Mustafa Abraham
(M)
Julianne Dangelo
(J)
Jordan Hegedus
(J)
Ian Jones
(I)
Alexander Junglas
(A)
Jihyun Lee
(J)
Jadin Nettles
(J)
Curtis Mitchell
(C)
Mawada Osman
(M)
Gloria Scott-Tibbs
(G)
Loraine Sinnott
(L)
Chloe Teasley
(C)
Victor Vang
(V)
Robin Varghese
(R)
Informations de copyright
© 2022 College of Optometrists.
Références
Ophthalmology. 2021 Dec;128(12):1756-1765
pubmed: 34172337
Optom Vis Sci. 2019 Nov;96(11):825-835
pubmed: 31651593
Open Ophthalmol J. 2018 Feb 28;12:12-18
pubmed: 29541278
Optom Vis Sci. 2009 Apr;86(4):357-63
pubmed: 19289977
Middle East Afr J Ophthalmol. 2015 Jan-Mar;22(1):97-102
pubmed: 25624682
Optom Vis Sci. 2003 Dec;80(12):832-8
pubmed: 14688547
J Ophthalmic Vis Res. 2018 Jul-Sep;13(3):307-314
pubmed: 30090188
Cochrane Database Syst Rev. 2020 Dec 2;12:CD006768
pubmed: 33263359
Arch Ophthalmol. 2005 Jan;123(1):14-24
pubmed: 15642806
Arch Ophthalmol. 2008 Oct;126(10):1336-49
pubmed: 18852411
Optom Vis Sci. 2010 Aug;87(8):593-603
pubmed: 20543758
Ophthalmic Physiol Opt. 2021 Jan;41(1):21-32
pubmed: 33119180
Vis Dev Rehabil. 2015 Oct;1(3):214-228
pubmed: 26942226
Optometry. 2012 Apr 30;83(4):137-58
pubmed: 23231437
Optom Vis Sci. 2020 Dec;97(12):1061-1069
pubmed: 33186192
Optom Vis Sci. 2019 Nov;96(11):836-849
pubmed: 31651592